CJC-1295 With DAC vs CJC-1295 No DAC: Key Differences in Laboratory Research Applications
CJC-1295 With DAC vs CJC-1295 No DAC: Key Differences in Laboratory Research Applications
Researchers working with growth hormone-releasing hormone (GHRH) analogs often encounter two closely related compounds: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC. While both are synthetic GHRH peptides studied for their ability to stimulate growth hormone release in preclinical models, they behave very differently in laboratory settings. Understanding those differences is essential for designing experiments, selecting appropriate research peptides, and interpreting results accurately.
This article breaks down the key structural, pharmacokinetic, and functional distinctions between the two variants, as documented in peer-reviewed research using in vitro and animal models.
Disclaimer: CJC-1295 (with or without DAC) is a research chemical intended strictly for laboratory and scientific investigation. It is not approved for human or veterinary use by the FDA or any other regulatory body. All information provided here is for educational and research purposes only. Palmetto Peptides supplies research-grade peptides exclusively for qualified laboratory use in compliance with all applicable laws and regulations.
What Is CJC-1295 and How Do the Two Variants Differ?
CJC-1295 is a tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH[1-29]), modified to resist enzymatic degradation and extend bioactivity in research models. Both variants share the same core amino acid sequence but differ in one critical structural modification: the presence or absence of a lysine-maleimide Drug Affinity Complex (DAC).
The DAC modification enables the peptide to covalently bind to serum albumin, drastically extending its half-life. Without the DAC, CJC-1295 (also referred to as Modified GRF 1-29 or Mod GRF 1-29 in research literature) is cleared from circulation much more rapidly.
Core Structural Comparison
| Feature | CJC-1295 With DAC | CJC-1295 Without DAC (Mod GRF 1-29) |
|---|---|---|
| Molecular Weight | ~3,647 Da | ~3,367 Da |
| DAC Modification | Yes (maleimide-lysine) | No |
| Albumin Binding | Covalent | None |
| Half-Life (Animal Models) | ~6 to 8 days | ~30 minutes |
| Primary Research Use | Sustained GH pulse studies | Acute, pulsatile GH release studies |
| Degradation Resistance | High | Moderate |
Pharmacokinetic Profiles in Research Models
CJC-1295 With DAC: Extended Bioactivity
The addition of the DAC moiety allows CJC-1295 to form a covalent bond with cysteine-34 on serum albumin once introduced into a biological system. This binding effectively turns albumin into a slow-release reservoir for the peptide.
Studies in rodent models have demonstrated that CJC-1295 with DAC produces sustained elevations in plasma GH and insulin-like growth factor 1 (IGF-1) lasting days after a single administration. Teichman et al. (2006) published foundational research in the Journal of Clinical Endocrinology and Metabolism showing that this DAC-modified peptide produced mean GH elevations persisting for more than six days in a pharmacokinetic study. It is important to note this research was observational and the compound has not received regulatory approval for clinical use.
For laboratory researchers, the extended half-life makes CJC-1295 with DAC well-suited for:
- Studies examining chronic or sustained GH axis stimulation in animal models
- Long-term IGF-1 response studies
- Experimental protocols where frequent dosing would introduce confounding variables
CJC-1295 Without DAC: Pulsatile Research Model
CJC-1295 without DAC lacks albumin-binding capability and is cleared relatively quickly in biological systems. This makes it pharmacokinetically similar to endogenous GHRH, which is released in pulses from the hypothalamus.
In laboratory applications, the no-DAC variant is preferred when researchers wish to mimic the physiological, pulsatile pattern of GH secretion. This variant is also commonly studied in combination with GH secretagogues such as ipamorelin, which act on different receptor pathways and can produce additive or synergistic effects on GH release.
Receptor Binding and Mechanism Differences
Both variants interact with the GHRH receptor (GHRHR) on pituitary somatotroph cells. Their receptor affinity is broadly similar at the binding site level, as the core GHRH analog sequence is unchanged. However, the DAC modification introduces differences in how each compound presents to the receptor over time.
With DAC, albumin-bound peptide provides a slow, continuous trickle of free peptide available to bind GHRHR. This blunts the peak amplitude of individual GH pulses but prolongs total GH output. Without DAC, a more concentrated bolus of peptide reaches GHRHR simultaneously, producing a more pronounced but shorter-lived GH spike.
These differences have meaningful implications for experimental design. Researchers studying pituitary sensitivity, receptor downregulation, or desensitization may see different outcomes depending on which variant they use, and those outcomes will not be directly comparable between studies.
Research Applications: Which Variant for Which Study?
Use CJC-1295 With DAC When:
- Studying sustained GH axis activation over days or weeks in animal models
- Investigating long-term changes in IGF-1 or downstream anabolic signaling pathways
- Designing protocols where frequent administration would compromise animal welfare or introduce confounding stress responses
- Examining chronic effects of GHRH receptor stimulation on pituitary morphology or gene expression
Use CJC-1295 Without DAC When:
- Modeling physiological pulsatile GH secretion in rodent or cell-based systems
- Studying immediate neuroendocrine responses to GHRH receptor activation
- Combining with GH secretagogues for acute synergy studies
- Short-duration in vitro or ex vivo experiments where compound half-life is less relevant
Stability and Storage Considerations in the Lab
Both variants share similar stability profiles when lyophilized. Store at -20 degrees Celsius or below in a dry, dark environment. Once reconstituted in sterile bacteriostatic water, solutions should be kept at 2 to 8 degrees Celsius.
For the DAC variant specifically: avoid thiol-containing buffers such as DTT or beta-mercaptoethanol. These react with the maleimide group and inactivate the albumin-binding modification. Neutral to slightly acidic pH (6.5 to 7.0) is optimal for DAC stability.
Quality Control: Why Variant Confirmation Matters
Because both compounds share a similar core sequence, inferior or poorly characterized research peptides may be mislabeled. Third-party purity testing and certificate of analysis (COA) documentation is non-negotiable in serious research contexts. The DAC variant has a molecular weight of approximately 3,647 Da; the no-DAC variant approximately 3,367 Da. Mass spectrometry confirmation readily distinguishes the two.
At Palmetto Peptides, all CJC-1295 variants are independently tested for purity by HPLC and confirmed by mass spectrometry. Lot-specific COA documentation is available from each product listing.
Research-grade CJC-1295 is available from Palmetto Peptides for qualified laboratory researchers.
Related Research
- Complete Guide to CJC-1295
- Mechanism of Action of CJC-1295
- CJC-1295 Pharmacokinetics and Half-Life
- CJC-1295 and Ipamorelin Stack Research
- Storing and Handling CJC-1295 Research Peptides
- Reconstitution Protocols for CJC-1295
Frequently Asked Questions
Can CJC-1295 with DAC and without DAC be used interchangeably in research studies? No. Their pharmacokinetic profiles differ substantially. The DAC variant produces sustained GH elevation over days; the no-DAC variant produces a shorter, more pulsatile response. Substituting one for the other would produce non-comparable experimental results.
Which variant is more commonly referenced in peer-reviewed literature? Both appear in the literature, often under different nomenclature. CJC-1295 with DAC is frequently referenced simply as "CJC-1295," while the no-DAC version is often called "Modified GRF 1-29" or "Mod GRF 1-29." Researchers should verify nomenclature carefully when reviewing published studies.
Does the DAC modification affect receptor binding affinity? The core GHRH analog sequence responsible for receptor binding is the same in both variants. The DAC modification primarily affects pharmacokinetics rather than receptor affinity directly.
Are there research settings where one variant is clearly preferred over the other? Yes. For chronic or longitudinal animal model studies, the DAC variant's extended activity is often more practical. For acute pulsatile studies or combination peptide research, the no-DAC variant more closely mimics physiological GHRH behavior.
How should these peptides be handled differently in the lab? The no-DAC variant should be handled like other standard GHRH analogs. The DAC variant requires additional care to avoid thiol-containing buffers that could cleave the maleimide group. Both should be stored lyophilized at -20 degrees Celsius and protected from light and moisture.
Summary
CJC-1295 with DAC and CJC-1295 without DAC are structurally related but functionally distinct research peptides. The DAC modification extends albumin binding and dramatically increases circulating half-life, making the DAC variant suitable for sustained GH axis stimulation studies. The no-DAC variant more closely mimics endogenous pulsatile GHRH activity and is preferred for acute-response and combination peptide research protocols. Proper identification, storage, and sourcing of each variant are essential for experimental validity.
References
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting growth hormone-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
- Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology. 2006;291(6):E1290-E1294.
Author: Palmetto Peptides Research Team | Last Updated: June 2025